MND NSW provides information, support and education for people living with motor neurone disease, their families, friends and carers in NSW, ACT, the Gold Coast and NT. We also provide information and education about motor neurone disease for health, community and residential care professionals.

  • 1

From 1 July 2017, the National Disability Insurance Scheme (NDIS) will be in place across all of NSW, with people living in Northern NSW, Mid North Coast, Sydney, South Eastern Sydney, Illawarra Shoalhaven, Murrumbidgee, Western NSW and Far West NSW joining those already able to access the NDIS. Upcoming Community Information Sessions, Plan Implementation Workshops and drop-in sessions for NSW, the ACT and NT during May/June include:

After our first night back in civilisation, it was a bit confusing to wake up in a bed, rather than a tent, and to use an ordinary toilet again! Another early start, up at 5am, ready to face and accept the challenge for the day by 6am. Before we could start our walking back at Machu Picchu, we first had to take the bus trip, this time in reverse of what we did yesterday afternoon.

Dr Brad Turner, The Florey Institute of Neuroscience and Mental Health Victoria and speaking with MND Victoria CEO, Rod Harris about the US announcement of Edaravone as a treatment for ALS and what this means for Australians. Great questions and informative answers.

Australia's MND March of Faces Banners are a photographic display of people with motor neurone disease. The MND NSW March of Faces banners are displayed at various MND awareness raising and remembrance events throughout the year. Our MND March of Faces Banners 18 and 19 were displayed for the first time during MND Week 2017.

The U.S. Food and Drug Administration (FDA) has approved the drug Radicava (edaravone) to treat ALS/MND in the USA. Shown to slow progression in some people, it is the first drug to be approved for ALS in over 20 years (it is anticipated Radicava will be available in the U.S. by August 2017). In 2015, edaravone was approved for use as an ALS treatment in Japan (as Radicut) and South Korea. Radicava is administered through an intravenous infusion and not yet approved for use in Australia under our country's regulatory approval process for drugs. In this report we provide information about edaravone and the Australian context.

Subscribe to news and updates

Visit Our Facebook Page


About us

What is MND NSW and what do we do?


Find out more about MND

Resources for families and health professionals



Support our work. Buy MND NSW merchandise here.


Including MND NSW in your Will

Leaving MND NSW a gift in your Will can make all the difference to people living with motor neurone disease.